Nautilus Biotechnology, Inc. (NAUT)
Nasdaq · Laboratory Analytical Instruments · Manufacturing · CIK 1808805 · fiscal year ends in Dec
Closing price $2.74 on 30 Oct 2026; 52-week range $0.85 to $3.95.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $348.9M
- Cash
- $10.5M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 127.3M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $234.0K | -$15.6M | -$0.12 |
| Q2 FY2026 | 30 Jun 2026 | $190.0K | -$14.5M | -$0.11 |
| Q3 FY2025 | 30 Sep 2025 | $0 | -$13.6M | -$0.11 |
| Q2 FY2025 | 30 Jun 2025 | $0 | -$15.0M | -$0.12 |
Company events
The newest 8-K filings of 43 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 27 Oct 2026 | 8-K | Results | 2.02, 9.01 |
| 11 Sep 2026 | 8-K | Material agreement, Agreement ended | 1.01, 1.02, 9.01 |
| 28 Jul 2026 | 8-K | Results | 2.02, 9.01 |
| 18 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 28 Apr 2026 | 8-K | Results | 2.02, 9.01 |
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Nov 2025 | 8-K | Other events | 8.01 |
| 28 Oct 2025 | 8-K | Results | 2.02, 9.01 |
| 31 Jul 2025 | 8-K | Results | 2.02, 9.01 |
| 23 Jun 2025 | 8-K | Shareholder vote | 5.07 |
| 2 May 2025 | 8-K | Delisting notice | 3.01 |
| 29 Apr 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 134 held.
| Filed | Form | Period |
|---|---|---|
| 27 Oct 2026 | 10-Q | 30 Sep 2026 |
| 27 Oct 2026 | 8-K | 27 Oct 2026 |
| 18 Sep 2026 | EFFECT | – |
| 11 Sep 2026 | 8-K | 11 Sep 2026 |
| 11 Sep 2026 | S-3 | – |
| 28 Jul 2026 | 10-Q | 30 Jun 2026 |
| 28 Jul 2026 | 8-K | 28 Jul 2026 |
| 18 Jun 2026 | 8-K | 17 Jun 2026 |
| 28 Apr 2026 | ARS | 31 Dec 2025 |
| 28 Apr 2026 | DEFA14A | – |
| 28 Apr 2026 | DEF 14A | 17 Jun 2026 |
| 28 Apr 2026 | 10-Q | 31 Mar 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 2 Jun 2026 | Ah Equity Partners Bio Ii, L.L.C., 10% owner | Sale outside a trading plan | 4,615,974 | $2.35 | $10.8M | 11,682,032 | 4 Jun 2026 |
| 2 Jun 2026 | Ah Equity Partners Bio Ii, L.L.C., 10% owner | Sale outside a trading plan | 384,026 | $2.35 | $902.5K | 971,885 | 4 Jun 2026 |
| 4 Mar 2026 | Patel Sujal M, CEO, President, and Secretary | Purchase | 25,000 | $2.61 | $65.2K | 10,366,721 | 4 Mar 2026 |
| 6 Nov 2025 | Suzuki Kentaro, Chief Marketing Officer | Purchase | 4,000 | $1.49 | $6.0K | 4,000 | 10 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 11 Sep 2026 | AH Bio Fund II, L.P. | 13D amended | 4.9% | 6.3M |
| 28 Aug 2026 | AH Bio Fund II, L.P. | 13D amended | 6% | 7.7M |
| 14 Aug 2026 | Perceptive Advisors LLC | 13D amended | 9.1% | 11.6M |
| 30 Jun 2026 | AH Bio Fund II, L.P. | 13D amended | 7.1% | 9.1M |
| 4 Jun 2026 | AH Bio Fund II, L.P. | 13D amended | 9.9% | 12.7M |
| 4 Mar 2026 | Parag Mallick | 13D amended | 17.6% | 22.6M |
| 4 Mar 2026 | Sujal Patel | 13D amended | 16.3% | 21.2M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 5.6M | -2.62% | 1 |
| 30 Sep 2026 | 5.8M | +41.38% | 1.42 |
| 15 Sep 2026 | 4.1M | +7.03% | 3.24 |
| 31 Aug 2026 | 3.8M | +20.9% | 6.44 |
| 14 Aug 2026 | 3.2M | +38.79% | 3.67 |
| 31 Jul 2026 | 2.3M | +56.9% | 2.72 |
| 15 Jul 2026 | 1.4M | +74.65% | 1.3 |
| 30 Jun 2026 | 829.5K | +53.29% | 1 |
Funds that hold it
From each fund's latest Form 13F.
110 funds held it at 30 Jun 2026: 59 added and 11 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Perceptive Advisors LLC | 11,634,211 | $21.8M | -960,000 |
| a16z Capital Management, L.L.C. | 9,063,054 | $16.9M | -8,590,863 |
| Cercano Management LLC | 7,172,985 | $13.4M | 0 |
| BlackRock, Inc. | 2,687,226 | $5.0M | +2,499,555 |
| Vanguard Capital Management LLC | 2,549,979 | $4.8M | +4,382 |
| Comprehensive Financial Management LLC | 2,207,619 | $4.1M | 0 |
| Citadel Advisors LLC | 1,896,192 | $3.5M | +1,896,192 |
| Geode Capital Management, LLC | 1,265,535 | $2.4M | +662,011 |
| Acadian Asset Management LLC | 1,055,461 | $2.0M | +314,215 |
| Clearstead Advisors, LLC | 892,787 | $1.7M | -1,436,997 |
Peers
Companies in the same industry.
- Agilent Technologies, Inc. (A): revenue $7.4B, market value $49.3B
- Waters Corp. (WAT): revenue $4.6B, market value $45.4B
- Mettler Toledo International Inc. (MTD): revenue $4.1B, market value $36.3B
- Illumina, Inc. (ILMN): revenue $4.5B, market value $35.7B
- Revvity, Inc. (RVTY): revenue $2.9B, market value $17.5B
- Avantor, Inc. (AVTR): revenue $6.6B, market value $10.9B
- Bio-Rad Laboratories, Inc. (BIO): revenue $2.6B, market value $10.0B
- 10x Genomics, Inc. (TXG): revenue $616.9M, market value $9.1B
- Bruker Corp. (BRKR): revenue $3.5B, market value $8.7B
- Alamar Biosciences, Inc. (ALMR): revenue –, market value $2.1B